Phenylhydrazine is a radioprotector when injected into mice 6 to 11 days before exposure to x-rays. To better define the basis for radioprotection, the following studies were made: effects of phenylhydrazine on <tex-math>${\rm LD}_{50(30)}$</tex-math>, hemopoietic regeneration in irradiated mice, hemopoiesis of unirradiated mice, hemopoietic cell radiosensitivity, and life-span of protected mice. Injection of 3.0 mg of the drug a week before irradiation increased the <tex-math>${\rm LD}_{50(30)}$</tex-math> by 140 R, which is equivalent to a dose reduction factor of about 1.2. Phenylhydrazine-treated mice survive because of hematologic recovery that becomes manifest 2 weeks after irradiation. Some of the results are consistent with the hypothesis that radioprotection by phenylhydrazine is the result of increased numbers of hemopoietic stem cells in the spleen at the time of irradiation. However, some of the colony-forming unit and splenectomy data indicate that this increase may not be the sole basis for protection, although it is clear that the spleen is involved. Protection by phenylhydrazine does not appear to be related to an increase in radioresistance of hemopoietic stem cells (colony-forming units) or to hypoxia resulting from anemia or from methemoglobin formation.
Skip Nav Destination
Close
Article navigation
1 June 1972
Research Article|
June 01 1972
Mechanisms of Radioprotection of Mice by Phenylhydrazine
Radiat Res (1972) 50 (3): 611–628.
Citation
L. H. Smith, T. W. McKinley,; Mechanisms of Radioprotection of Mice by Phenylhydrazine. Radiat Res 1 June 1972; 50 (3): 611–628. doi: https://doi.org/10.2307/3573558
Download citation file:
Close
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Sign in via your Institution
Sign in via your InstitutionCiting articles via
Commonalities Between COVID-19 and Radiation Injury
Carmen I. Rios, David R. Cassatt, Brynn A. Hollingsworth, Merriline M. Satyamitra, Yeabsera S. Tadesse, Lanyn P. Taliaferro, Thomas A. Winters, Andrea L. DiCarlo
Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?
Pataje G. Prasanna, Gayle E. Woloschak, Andrea L. DiCarlo, Jeffrey C. Buchsbaum, Dörthe Schaue, Arnab Chakravarti, Francis A. Cucinotta, Silvia C. Formenti, Chandan Guha, Dale J. Hu, Mohammad K. Khan, David G. Kirsch, Sunil Krishnan, Wolfgang W. Leitner, Brian Marples, William McBride, Minesh P. Mehta, Shahin Rafii, Elad Sharon, Julie M. Sullivan, Ralph R. Weichselbaum, Mansoor M. Ahmed, Bhadrasain Vikram, C. Norman Coleman, Kathryn D. Held
Germicidal Efficacy and Mammalian Skin Safety of 222-nm UV Light
Manuela Buonanno, Brian Ponnaiya, David Welch, Milda Stanislauskas, Gerhard Randers-Pehrson, Lubomir Smilenov, Franklin D. Lowy, David M. Owens, David J. Brenner
Photon GRID Radiation Therapy: A Physics and Dosimetry White Paper from the Radiosurgery Society (RSS) GRID/LATTICE, Microbeam and FLASH Radiotherapy Working Group
Hualin Zhang, Xiaodong Wu, Xin Zhang, Sha X. Chang, Ali Megooni, Eric D. Donnelly, Mansoor M. Ahmed, Robert J. Griffin, James S. Welsh, Charles B. Simone, II, Nina A. Mayr